Antibody-drug Conjugates (ADCs) are a growing class of targeted anti-cancer therapies, that combine the specific binding of an antibody with the toxic effects of chemotherapy. In developing new ADCs, one should take into consideration not only the affinity and binding properties of the antibody, but also its ability to internalize into the lysosome, where the conjugated drug is released. Here we describe how the use of confocal microscopy and Imaging Flow Cytometry (IFC) analyses assist in the process of ADC development. We show that the use of the Bright Detail Intensity (BDI) vs. the Bright Detail Similarity (BDS) features enables better selection of what we define as “best candidate to be used as an ADC” and discuss the advantages of using both confocal and IFC in combination, rather than each of these methods alone.
|Read the full article|
Authors: Mira Toister-Achituv ♦, Ziv Porat,* Doron Kalimi,* Ohad Tarcic, Nir Berger, Achim Doerner, Arie Zauberman [Author Information]
Key terms: Confocal Microscopy, ImageStream, IFC, Flow cytometry, Antibody drug conjugate (ADC), internalization, colocalization, Lysosome, BDI, BDS.
Published In: ADC Review| Journal of Antibody-drug Conjugates
How to cite:
Toister-Achituv M, Porat Z, Kalimi D, Tarcic O, Berger N, Doerner A, Zauberman A. Confocal Microscopy and Imaging Flow Cytometry – Tools for Selection of Antibodies to be Developed as Therapeutic ADCs – J. ADC. October 29, 2019. DOI: 10.14229/jadc.2019.10.29.001.
Last Editorial Review: October 24, 2019
- Original Manuscript Received October 15, 2019
- Review results received October 22, 2019
- Manuscript accepted for publication October 23, 2019
- First Published Online October 29, 2019.